ALPS Advisors’s Inhibrx INBX Stock Holding History

ALPS Advisors’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,952	Closed	-$172K	–	1020
2024 Q3	$172K	Sell	10,952 -324	-3%	-$4.55K	﹤0.01%	982
2024 Q2	$160K	Buy	+11,276	New	+$176K	﹤0.01%	957

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Slotnik Capital Dallas, Texas $342M AUM 105.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ALPS Advisors's INBX Position: Q4 2024 in Review

ALPS Advisors sold out of Inhibrx (INBX) in Q4 2024, closing a stake of 10,952 shares — an estimated $172K sold.

ALPS Advisors first reported a position in INBX in Q2 2024 and held it in 2 quarters. The position peaked at $172K in Q3 2024. 101 funds tracked by Wall St. Rank hold INBX as of Q4 2024.

ALPS Advisors reported no remaining Inhibrx position as of Q4 2024 after selling out during the quarter.
ALPS Advisors sold 10,952 Inhibrx shares in Q4 2024, an estimated $172K.
ALPS Advisors first reported a position in Inhibrx in Q2 2024 and held it in 2 quarters.
ALPS Advisors's Inhibrx position peaked at $172K in Q3 2024.
101 funds tracked by Wall St. Rank held Inhibrx as of Q4 2024.

Based on ALPS Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.